Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHARM > anti-infective > Flashcards

anti-infective Flashcards

1
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV-infected patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

Read this 4 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Indications for aerosolized _______?

Prevention of Pneumocystis pneumonia (PCP)
in HIV-infected patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

pentamidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Indications for ______ pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV-infected patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

aerosolized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Indications for aerosolized pentamidine

Prevention of ______ _______ in HIV-infected patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

Pneumocystis pneumonia (PCP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV-infected patients with history of ___ or
____ episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

One or more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in ______ patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

HIV-infected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV patients with history of one or
more episodes of PCP or a ______ (T4
helper cell) lymphocyte count of 200/mm3 or
less

A

peripheral CD4+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) _____ count of 200/mm3 or
less

A

lymphocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Indications for aerosolized pentamidine

Prevention of Pneumocystis pneumonia (PCP)
in HIV patients with history of one or
more episodes of PCP or a peripheral CD4+ (T4
helper cell) lymphocyte count of _____ or
_____

A

200/mm3 or Less

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Indications for aerosolized ribavirin

 Treatment of hospitalized infants with severe
lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

Read this 4 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Indications for aerosolized _____

 Treatment of hospitalized infants with severe
lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

ribavirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Indications for aerosolized ribavirin

 Treatment of hospitalized _____ with severe
lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

infants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indications for aerosolized ribavirin

 Treatment of hospitalized infants with severe
____ ______ _____ ______ caused by
respiratory syncytial virus (RSV)

A

lower respiratory tract infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Indications for aerosolized ribavirin

 Treatment of hospitalized infants with severe
lower respiratory tract infection caused by
______ ______ _______?

A

respiratory syncytial virus (RSV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indications for _____ ribavirin

 Treatment of hospitalized infants with severe
lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

aerosolized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indications for aerosolized ribavirin

 Treatment of______ infants with severe
lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

hospitalized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Indications for aerosolized ribavirin

 Treatment of hospitalized infants with _____ lower respiratory tract infection caused by
respiratory syncytial virus (RSV)

A

severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indications for aerosolized tobramycin

 Management of chronic Pseudomonas
aeruginosa infection in cystic fibrosis

A

Read 4 times

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indications for aerosolized _____

Management of chronic Pseudomonas
aeruginosa infection in cystic fibrosis

A

tobramycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Indications for aerosolized tobramycin

 Management of chronic ____ ______ infection in cystic fibrosis

A

Pseudomonas aeruginosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Indications for aerosolized tobramycin

 Management of chronic Pseudomonas
aeruginosa infection in _______ ______

A

cystic fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Indications for aerosolized tobramycin

 Management of _____ Pseudomonas
aeruginosa infection in cystic fibrosis

A

chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Indications for aerosolized tobramycin

________ of chronic Pseudomonas
aeruginosa infection in cystic fibrosis

A

Management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

 Indications for inhaled zanamivir

 Influenza virus in adults and children age 5
years or over, who have been symptomatic for
no more than 2 days

A

4 x

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

 Indications for inhaled zanamivir

_______ in adults and children age 5
years or over, who have been symptomatic for
no more than 2 days

A

Influenza virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

 Indications for inhaled zanamivir

 Influenza virus in adults and children age 5
years or over, who have been symptomatic for
no more than _ days

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

 Indications for inhaled zanamivir

 Influenza virus in adults and children age _
years or over, who have been symptomatic for
no more than 2 days

A

5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

 Indications for inhaled _____

 Influenza virus in adults and children age 5
years or over, who have been symptomatic for
no more than 2 days

A

zanamivir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

 Indications for inhaled zanamivir

 Influenza virus in adults and children age 5
years or over, who have been_____ for
no more than 2 days

A

symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

 Indications for inhaled zanamivir

 Influenza virus in _____ and _____ age 5
years or over, who have been symptomatic for
no more than 2 days

A

adults and children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

 Indications for inhaled zanamivir

 Influenza virus in adults and children age 5
years or over, who have been symptomatic for
_____ ____ than 2 days

A

no more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What would you give infants with severe lower respiratory tract infection caused by respiratory syncytial virus (RSV)

A

ribavirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Pentamidine Trade name

A

NebuPent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Pentamidine/NebuPent dosage

A

300mg powder in

6mL sterile water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Pentamidine/NebuPent Frequency

A

Once per month

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Pentamidine/NebuPent Indications

A

PCP

Prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What drug would be given for Management of chronic Pseudomonas aeruginosa infection in cystic fibrosis

A

tobramycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Ribavirin trade name

A

Virazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Ribavirin/Virazole dosage

A

6g powder in

300mL sterile water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Ribavirin/Virazole frequency

A

12-18 hr/day for 3-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Ribavirin/Virazole Route

A

SPAG NEB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Ribavirin/Virazole Indication

A

(RSV) respiratory syncytial virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What medicine would you give for Influenza virus in adults and children age 5 years or over, who have been symptomatic for no more than 2 days

A

zanamivir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Tobramycin trade name

A

TOBI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Tobramycin/TOBI dosage

A

300 mg/5mL ampule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Tobramycin/TOBI Frequency

A

28 days

on 28 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Tobramycin/TOBI Indications

A

Pseudomonas

aeruginosa in CF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

INDICATIONS for these medications

A

Used as adjunct to systemic therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

For topical deposition of agents inappropriate

for systemic administration

A

Nystatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

For topical deposition with pulmonary
infection where perfusion is limited and
systemic therapy has failed

A

aspergillosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

For topical deposition of agent that is more

effective by this route

A

pentamidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Indication

To eliminate an organism that is colonizing
the _____ ______(infected sputum in
cystic fibrosis of bronchiectasis)

A

respiratory tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Indication

To reduce the severity of ______ _____ ____(some agents are poorly absorbed in
the lungs)

A

systemic side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient \_\_\_\_\_\_
Bronchospasm
 Systemic side effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be deposited in desired site
 Dosages have not been determined
A

dependent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 \_\_\_\_\_\_\_\_\_
 Systemic side effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be deposited in desired site
 Dosages have not been determined
A

Bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 \_\_\_\_\_\_ \_\_\_\_\_\_ effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be deposited in desired site
 Dosages have not been determined
A

Systemic side

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 Systemic side effects may occur
 Drugs may be \_\_\_\_\_\_\_ by sputum 
proteins
 Drug may not be deposited in desired site
 Dosages have not been determined
A

inactivated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 Systemic side effects may occur
 Drugs may be inactivated by \_\_\_\_ \_\_\_\_
 Drug may not be deposited in desired site
 Dosages have not been determined
A

sputum proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 Systemic side effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be \_\_\_\_\_\_\_  in desired site
 Dosages have not been determined
A

deposited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 Systemic side effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be deposited in desired site
 Dosages have not been \_\_\_\_\_\_
A

determined

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q 
LIMITATIONS -DISADVANTAGES
 Therapy is patient dependent
 Bronchospasm
 Systemic side effects may occur
 Drugs may be inactivated by sputum 
proteins
 Drug may not be deposited in desired site
 \_\_\_\_\_\_ have not been determined
A

Dosages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Optimal delivery and equipment techniques

have not been determined

A

hmmm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

AEROSOLIZED PENTAMIDINE
 Anti-protozoal agent is the agent against P.
carinii, agent for PCP
 Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of ≤ 200/mm3.
 If given IV or IM the drug goes to liver,
kidneys and pancreas. Bind to tissues.
 Can be seen in urine 270 days later

A

Read this

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

AEROSOLIZED PENTAMIDINE
 _____-_____ agent is the agent against P.
carinii, agent for PCP

A

Anti-protozoal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

AEROSOLIZED PENTAMIDINE

 Anti-protozoal agent is the agent against ____ _____, agent for PCP

A

P. carinii

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

AEROSOLIZED PENTAMIDINE

 Preventative as_____-_____ for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of ≤ 200/mm3.

A

Second-line

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

AEROSOLIZED PENTAMIDINE

 Preventative as second-line for PCP in high
–risk ___ pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of ≤ 200/mm3.

A

HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

AEROSOLIZED PENTAMIDINE
  Preventative as second-line for PCP in high
–risk HIV pts who have a history of ____________ of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of ≤ 200/mm3.

A

One or more episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

AEROSOLIZED PENTAMIDINE

 Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a __________
(T4 helper cell) lymphocyte count
of ≤ 200/mm3.

A

peripheral CD4+

70
Q

AEROSOLIZED PENTAMIDINE
  Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (______) lymphocyte count
of ≤ 200/mm3.

A

(T4 helper cell)

71
Q

AEROSOLIZED PENTAMIDINE
  Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) _______ count
of ≤ 200/mm3.

A

lymphocyte

72
Q

AEROSOLIZED PENTAMIDINE
  Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of _______

A

≤ 200/mm3.

73
Q

AEROSOLIZED PENTAMIDINE

If given_______ the drug goes to liver,
kidneys and pancreas. Bind to tissues.

A

IV or IM

74
Q

AEROSOLIZED PENTAMIDINE

If given IV or IM the drug goes to____,
kidneys and pancreas. Bind to tissues.

A

liver

75
Q

AEROSOLIZED PENTAMIDINE

If given IV or IM the drug goes to liver,
______ and pancreas. Bind to tissues.

A

kidneys

76
Q

AEROSOLIZED PENTAMIDINE

If given IV or IM the drug goes to liver,
kidneys and ______. Bind to tissues.

A

pancreas

77
Q

AEROSOLIZED PENTAMIDINE

If given IV or IM the drug goes to liver,
kidneys and pancreas. Bind to______.

A

tissues

78
Q

AEROSOLIZED PENTAMIDINE

Can be seen in ____ 270 days later

A

urine

79
Q

AEROSOLIZED ______________
 Anti-protozoal agent is the agent against P.
carinii, agent for PCP
 Preventative as second-line for PCP in high
–risk HIV pts who have a history of one or
more episodes of PCP or a peripheral
CD4+ (T4 helper cell) lymphocyte count
of ≤ 200/mm3.
 If given IV or IM the drug goes to liver,
kidneys and pancreas. Bind to tissues.
 Can be seen in urine 270 days later

A

PENTAMIDINE

80
Q 
AEROSOLIZED PENTAMIDINE
 Usually lies dormant in lung.
 If immunosuppressed - develops
 Causes a foamy intraalveolar exudate, 
which contains cysts of P.carinii
 Approved by RespiGuardII neb
 SVN fitted with a series of one-way valves 
and an expiratory filter
A

read

81
Q

AEROSOLIZED PENTAMIDINE

 Usually lies _____ in lung.

A

dormant

82
Q

AEROSOLIZED PENTAMIDINE

 If _______ - develops

A

immunosuppressed

83
Q

AEROSOLIZED PENTAMIDINE

Causes a foamy______ ______,
which contains cysts of P.carinii

A

intraalveolar exudate

84
Q

AEROSOLIZED PENTAMIDINE

Causes a foamy intraalveolar exudate,
which contains cysts of ________

A

P.carinii

85
Q

AEROSOLIZED PENTAMIDINE

Causes a foamy intraalveolar exudate,
which contains _____ of P.carinii

A

cysts

86
Q

AEROSOLIZED PENTAMIDINE

Approved by _______ neb

A

RespiGuardII

87
Q

AEROSOLIZED PENTAMIDINE

SVN fitted with a series of ___-_____ valves
and an expiratory filter

A

one-way

88
Q

AEROSOLIZED PENTAMIDINE

SVN_____ with a series of one-way valves
and an expiratory filter

A

fitted

89
Q

AEROSOLIZED PENTAMIDINE

SVN fitted with a series of one-way valves
and an _____ _____

A

expiratory filter

90
Q

 Description of PCP

________ usually infected at early age
 Disease occurs when there is suppression of the
immune system
 a.k.a. Pneumocystis jiroveci

A

Mammals

91
Q 
Description of PCP
 Mammals usually infected at early age
 Disease occurs when there is suppression of the 
\_\_\_\_\_\_\_\_
 a.k.a. Pneumocystis jiroveci
A

immune system

92
Q

 Rationale for aerosol administration

______ targeted lung delivery, with fewer or less
severe side effects compared with systemic
administration

A

Local

93
Q

 Rationale for aerosol administration

Local targeted lung delivery, with _____ _____
severe side effects compared with systemic
administration

A

fewer or less

94
Q

 Rationale for aerosol administration

Local targeted lung delivery, with fewer or less
severe _____ ______ compared with systemic
administration

A

side effects

95
Q

 Rationale for aerosol administration

Local targeted lung delivery, with fewer or less
severe side effects compared with _______
administration

A

systemic

96
Q

Description of PCP

 a.k.a. ______ ________

A

Pneumocystis jiroveci

97
Q 
Dosage and Administration
 Dosage
 300 mg, given by inhalation once every 4 
     weeks 
 NebuPent
 Dry powder (with 300 mg/vial)
 Reconstituted with 6 ml of sterile water 
 Not saline (can cause precipitation)
A

read

98
Q

Dosage for PENTAMIDINE

A

300mg

99
Q

How often should PENTAMIDINE given?

A

Once every 4 weeks

100
Q

What is the route PENTAMIDINE

A

Dry powder (with 300 mg/vial)

maybe also SVN? idk this is the 100th card…

101
Q

PENTAMIDINE

Reconstituted with 6 ml of ______

A

Sterile Water

102
Q

PENTAMIDINE

What can’t you use? and why?

A

Saline, because it causes precipitation

103
Q

Administration PENTAMIDINE
 Respirgard II nebulizer
 Escaped particles may be filtered to limit
exposure of healthcare workers
 Nebulizer performance
 Mass median diameter (MMD) of 1 to 2 μm

A

read

104
Q

Administration PENTAMIDINE

what kind of nebulizer

A

Respirgard II

105
Q

Administration PENTAMIDINE

Mass median diameter (MMD) of ______ ____

A

1 to 2 μm

106
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
 The exact mode of action not known 

    Blocks RNA and DNA synthesis, inhibits oxidative phosphorylation, and interferes with folate 
transformation

 75% of the drug is excreted in urine and 25% in
feces

A

read

107
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
 

A

The exact mode of action not known

108
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
Blocks\_\_\_\_ and \_\_\_\_\_ synthesis, inhibits oxidative phosphorylation, and interferes with folate 
transformation
A

RNA and DNA

109
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
Blocks RNA and DNA synthesis, inhibits \_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_, and interferes with folate 
transformation
A

oxidative phosphorylation

110
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
Blocks RNA and DNA synthesis, inhibits oxidative phosphorylation, and interferes with \_\_\_\_\_
transformation
A

folate

111
Q 
Dosage and Administration PENTAMIDINE
 
Mode of action
\_\_\_\_\_ RNA and DNA synthesis, \_\_\_\_\_\_ oxidative phosphorylation, and \_\_\_\_\_\_with folate 
transformation
A

Blocks
inhibits
interferes

112
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

Pain, swelling, and abscess formation at the site of injection, with intramuscular administration

 Thrombophlebitis and urticarial eruptions, with intravenous administration

 Hypoglycemia (up to 62% of patients), with a cumulative cytotoxic effect on pancreatic beta cells

 Impaired renal function and azotemia
 Hypotension
 Leukopenia
 Hepatic dysfunction

A

read

113
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

Pain, swelling, and abscess formation at the site of injection, with _______ _________

A

intramuscular administration

114
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration

Thrombophlebitis and urticarial eruptions, with ________ administration

A

intravenous

115
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration

_________ and urticarial eruptions, with intravenous administration

A

Thrombophlebitis

116
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration

Thrombophlebitis and_________, with intravenous administration

A

urticarial eruptions

117
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

________ (up to 62% of patients), with a cumulative cytotoxic effect on pancreatic beta cells

A

Hypoglycemia

118
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

Hypoglycemia (up to 62% of patients), with a cumulative______ effect on pancreatic beta cells

A

cytotoxic

119
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

Hypoglycemia (up to 62% of patients), with a cumulative cytotoxic effect on pancreatic ____ cells

A

beta

120
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

 Impaired\_\_\_\_\_\_\_ and azotemia  Hypotension  Leukopenia  Hepatic dysfunction
A

renal function

121
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

 Impaired renal function and \_\_\_\_\_\_  Hypotension  Leukopenia  Hepatic dysfunction
A

azotemia

122
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

 Impaired renal function and azotemia  \_\_\_\_\_\_\_  Leukopenia  Hepatic dysfunction
A

Hypotension

123
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

 Impaired renal function and azotemia  Hypotension \_\_\_\_\_\_\_\_  Hepatic dysfunction
A

Leukopenia

124
Q

Dosage and Administration PENTAMIDINE
 Side effects (parenteral administration)

     Impaired renal function and azotemia
 Hypotension
     Leukopenia
\_\_\_\_\_\_\_\_

A

Hepatic dysfunction

125
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

 Cough and bronchial irritation in 36% of patients in one study

 Shortness of breath

 Bad taste (bitter or burning) of the aerosol impacting in the oropharynx

 Bronchospasm and wheezing in 11% of patients
 Spontaneous pneumothoraces
 Conjunctivitis
 Rash
 Neutropenia
 Pancreatitis
 Renal insufficiency
 Dysglycemia (hypoglycemia and diabetes)
 Digital necrosis in both feet
 Appearance of extrapulmonary P. jiroveci infection

A

READ

126
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

______ and _______ irritation in 36% of patients in one study

A

Cough and bronchial

127
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

_____ of breath

A

Shortness

128
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Bad taste (bitter or burning) of the aerosol impacting in the ______

A

oropharynx

129
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

______ and _______ in 11% of patients

A

Bronchospasm and wheezing

130
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Spontaneous ________?

A

pneumothoraces

131
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration) 
    \_\_\_\_\_\_\_\_\_\_\_
 Rash
 Neutropenia
 Pancreatitis
 Renal insufficiency
A

Conjunctivitis

132
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration) 
     Conjunctivitis
 \_\_\_\_\_\_
 Neutropenia
 Pancreatitis
 Renal insufficiency
A

Rash

133
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration) 
 Conjunctivitis
 Rash
 Neutropenia
 Pancreatitis
 \_\_\_\_\_\_\_
A

Renal insufficiency

134
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration) 
    Conjunctivitis
 Rash
 \_\_\_\_\_\_\_
 Pancreatitis
 Renal insufficiency
A

Neutropenia

135
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)  
    Conjunctivitis
 Rash
 Neutropenia
 \_\_\_\_\_\_\_
 Renal insufficiency
A

Pancreatitis

136
Q 
Dosage and Administration PENTAMIDINE
 Side effects (\_\_\_\_\_\_ administration)

 Cough and bronchial irritation in 36% of patients in one study

 Shortness of breath

 Bad taste (bitter or burning) of the aerosol impacting in the oropharynx

 Bronchospasm and wheezing in 11% of patients
 Spontaneous pneumothoraces
 Conjunctivitis
 Rash
 Neutropenia
 Pancreatitis
 Renal insufficiency
 Dysglycemia (hypoglycemia and diabetes)
 Digital necrosis in both feet
 Appearance of extrapulmonary P. jiroveci infection

A

aerosol

137
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

_______ (hypoglycemia and diabetes)

A

Dysglycemia

138
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Digital _____ in both feet

A

necrosis

139
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Digital necrosis in both ____

A

feet

140
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Appearance of extrapulmonary _______ infection

A

P. jiroveci

141
Q 
Dosage and Administration PENTAMIDINE
 Side effects (aerosol administration)

Appearance of ______ P. jiroveci infection

A

extrapulmonary

142
Q 
Dosage and Administration PENTAMIDINE
 Preventing airway effects
 β-Adrenergic bronchodilator
 Parasympatholytic 
 Small particle size
 Reduces airway impaction and increases      alveolar deposition
A

read

143
Q 
Dosage and Administration PENTAMIDINE
 \_\_\_\_\_\_\_\_ airway effects
 β-Adrenergic bronchodilator
 Parasympatholytic 
 Small particle size
 Reduces airway impaction and increases      alveolar depositiondeposition
A

Preventing

144
Q 
Dosage and Administration PENTAMIDINE
 Preventing airway effects
_-\_\_\_\_\_\_\_ bronchodilator
 Parasympatholytic 
 Small particle size
 Reduces airway impaction and increases      alveolar deposition
A

β-Adrenergic

145
Q 
Dosage and Administration PENTAMIDINE
 Preventing airway effects
 β-Adrenergic bronchodilator
 \_\_\_\_\_\_\_\_\_\_\_\_
 Small particle size
 Reduces airway impaction and increases      alveolar deposition
A

Parasympatholytic

146
Q 
Dosage and Administration PENTAMIDINE
 Preventing airway effects
 β-Adrenergic bronchodilator
 Parasympatholytic 
 \_\_\_\_\_\_ particle size
 Reduces airway impaction and increases      alveolar deposition
A

Small

147
Q 
Dosage and Administration PENTAMIDINE
 Preventing airway effects
 β-Adrenergic bronchodilator
 Parasympatholytic 
 Small particle size
 \_\_\_\_\_\_ airway impaction and\_\_\_\_\_\_\_ alveolar deposition
A

Reduces; increases

148
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per hour, or consider using an isolation booth/hood assembly with an exhaust fan and air directed through a high-efficiency filter
 Use barrier protection (gloves, mask, eyewear) for healthcare workers
 Screen patients with HIV infection for TB, and treat where evidence of infection exists
 Do not allow treatment patients to mix with others until coughing subsides
 Healthcare workers should periodically screen
themselves for TB
 Pregnant women and nursing mothers should avoid exposure to the drug and all practitioners should limit

A

Read

149
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Administer aerosol in a
______-_____ room, with six air changes per hour, or consider using an isolation booth/hood assembly with an exhaust fan and air directed through a high-efficiency filter

A

negative-pressure

150
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Administer aerosol in a negative-pressure room, with ___ air changes per hour, or consider using an isolation booth/hood assembly with an exhaust fan and air directed through a high-efficiency filter

A

six

151
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per hour, or consider using an _____ ______/____ assembly with an exhaust fan and air directed through a high-efficiency filter

A

isolation booth/hood

152
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per ____, or consider using an isolation booth/hood assembly with an exhaust fan and air directed through a high-efficiency filter

A

hour

153
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per hour, or consider using an isolation booth/hood assembly with an____ _____ and air directed through a high-efficiency filter

A

exhaust fan

154
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per hour, or consider using an isolation booth/hood assembly with an exhaust fan and air directed through a _____-_____ filter

A

high-efficiency

155
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

 Administer aerosol in a negative-pressure room, with six air changes per hour, or consider using an ______ booth/hood assembly with an exhaust fan and air directed through a high-efficiency filter

A

isolation

156
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Use _____ protection (gloves, mask, eyewear) for healthcare workers

A

barrier

157
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Screen patients with _____ _____ for TB, and treat where evidence of infection exists

A

HIV infection

158
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Screen patients with HIV infection for ___, and treat where evidence of infection exists

A

TB

159
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Do not allow treatment patients to ____ with others until coughing subsides

A

mix

160
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Do not allow treatment patients to mix with others until ______ subsides

A

coughing

161
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions

Healthcare workers should periodically screen
themselves for ___

A

TB

162
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions 

_______ and nursing mothers should avoid exposure to the drug and all practitioners should limit

A

Pregnant women

163
Q

Dosage and Administration PENTAMIDINE
Additional environmental precautions 

Pregnant women and _________ should avoid exposure to the drug and all practitioners should limit

A

nursing mothers

164
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 _______-_____ –sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

Oral trimethoprim

165
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–________ (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

sulfamethoxazole

166
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for ______ of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

prophylaxis

167
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from ____-____ were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

TMP–SMX

168
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were _______ _____

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

absent or acceptable

169
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was _________ was therapy for prophylaxis of PCP

A

not recommended

170
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for prophylaxis of PCP

A

READ

171
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 Aerosolized pentamidine was not recommended as therapy for _______ of PCP

A

prophylaxis

172
Q

Aerosol therapy for prophylaxis of
Pneumocystis carinii pneumonia: Clinical
application

 2004 CDC recommendations

 Oral trimethoprim–sulfamethoxazole (TMP–SMX) was preferred for prophylaxis of PCP, as long as adverse side effects from TMP–SMX were absent or acceptable

 ______ _______ was not recommended as therapy for prophylaxis of PCP

A

Aerosolized pentamidine

PHARM (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions